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Introduction 
 
 
Lung transplantation is viable, and at some cases, the only treatment in patients with 
end stage lung diseases. Excluding lung cancer, nearly all chronic lung diseases may be 
indications for lung transplantation for nonsmoking patients. Lung transplantations 
have shown a huge progress during the last 10 years and it has been established as a 
treatment for patients with difficult lung disease. Since lung transplantation is 
relatively new treatment, there are still many unknown aspects, especially in relation 
to risk factors for chronic graft dysfunction (CGD). 
This study concentrates on the use of Oil-red-O (ORO) staining of bronchoalveolar 
lavage fluid macrophages as a possible indicator of chronic microaspiration in lung 
transplant patients. ORO staining is thought to reveal lipid-laden macrophages in 
bronchoalveolar lavage sample, which can be an indicator for reflux and 
microaspiration. Reflux and microaspiration are identified risk factors for bronchiolitis 
obliterans syndrome (BOS) which finally causes the loss of graft function and death. 
In the faculty of medicine in Helsinki University, we analyzed ORO samples of 54 lung 
transplant patients in Finland during a follow-up period of three years from protocol 
bronchoalveolar lavage (BAL) samples in order to find out whether ORO positivity 
corresponds with any medical event, for example rejections, BOS development or 
reflux symptoms. If so, ORO staining could be used in lung transplantation patients’ 
diagnostics predicting graft function. After initial screening of all 54 patients, the study 
cohort was narrowed down to a subcohort cohort of 22 transplantation patients, 
whose BAL macrophages showed the most prominent frequency and numbers for ORO 
staining. According to earlier investigations, ORO positivity in alveolar macrophages 
has been linked to the above-mentioned medical events.  
2 
 
 
Literature review 
 
 
Lung transplantation in Finland 
 
In Finland, the first lung transplantation was made in 1990 and currently 127 adult 
patients have received a lung transplant including heart-lung, single lung and double 
lung transplantations (Halme, personal communication 2014). The patients’ 1-year 
survival is 95% and 5-year survival is over 80%. Most of the transplant patients 
estimate that their quality of life after transplantation corresponds to normal 
population levels. In Western countries, the yield of usable transplants restricts the 
lung transplantation operations. In Finland, the waiting time for lung transplantation 
has been internationally short, for only 6-8 weeks on average. Indications for lung 
transplantation are the same internationally, but in Finland, pulmonary fibrosis is a 
more common indication for lung transplantation in comparison to patients that have 
COPD. If the patients get the lung transplant in time, the intensive care period in a 
hospital is significantly shorter and nowadays some patients have been able to go 
home in even after 12 days from the transplantation. (36) 
 
Bronchiolitis obliterans syndrome 
 
Despite the excellent prognosis of lung transplant patients, there are many severe 
complications. The meticulous and regular use of immunosuppressive medication, 
physical rehabilitation and family support are key treatments for these patients. 
Failure of lung transplantation is often caused by the development of bronchiolitis 
obliterans syndrome (BOS) where small airways are compressed and obstructed by 
chronic inflammation and fibrosis. Clinically, this leads to a progressive airflow 
limitation and a decline in FEV1 (forced expiratory volume in 1s). BOS is classified by a 
scale 1-3 where 3 is the most severe form. It is a diverse complication of lung 
transplantation where some patients go throw a rapid loss of lung function while in 
others it is a slow progression with long plateaus (1). Anyhow, transplant (ISHLT) 
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register reports that up to 48% of lung transplant patients will develop BOS within five 
years following the surgery and 76% after ten years. In addition every other patient 
may undergo acute rejection episodes during the first year after surgery. (36) 
Obliterative bronchiolitis (OB) is histological correlate of BOS (2). Chronic lung allograft 
dysfunction (chronic rejection) is histologically most often seen as OB which 
component’s consists of cellular and humoral allo- and autoimmunity and innate 
immunity (2). Overall the patophysiology of BOS is largely unknown and it is difficult to 
diagnose. Therefore BOS is not usually defined histologically but mostly by the loss of 
pulmonary function. Additional diagnostic tools can also be used, such as computed 
tomographic scans which can reveal air trapping during exhalation which is one of the 
most characteristic features and earlier signs for BOS  (3,4), bronchoalveolar lavage 
(BAL) analysis and transbronchial biopsy which gives and histological diagnose. The 
development of BOS in a lung transplant patient is considered an irreversible process. 
In the most severe cases there is no other treatment except retransplantation. 
Therefore it is crucial to prevent BOS development by reducing risk. 
The development of BOS is postulated to be linked with many factors which many 
require further analysis. Probable risk factors include acute rejection (4-11), 
bronchiolitis  (7,11-13) cytomegalovirus (4,9,10,14,15) and non-compliance to 
medication (16,17). Other risk factors include age, graft ischemic time, infections (1) 
and gastroesophageal reflux with aspiration (18).  
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Gastroesophageal reflux disease, aspiration and acute rejection 
 
Gastroesophageal reflux disease (GERD) has been documented to be prevalent in lung 
disease patients (18). Over a half of the idiopathic pulmonary fibrosis (IPF) patients and 
over a 65% of patients with other terminal lung disease have esophageal reflux.   
(19,20). GERD is common also after lung transplantation, with an incidence of nearly 
75% (21), largely because of graft denervation, vagal nerve injury during the operation, 
medication-induced gastroparesis, general anesthesia and immobility (22,23). 
Aspirated gastric contents due to GERD can lead to epithelial injury in the airways if 
prolonged and that may lead to inflammation (18,22). Innate immunity can be 
triggered by infections or by these chemical injuries and cause dendritic cell activation 
which leads to adaptive immunity toward epithelial cells. Inflammation may also favor 
rejection episodes increasing alloantigen expression (22). Acute cellular rejection is the 
most common form of acute rejection. It is mediated by T-cells which bind to MHC-
complexes which are presented in donor cells. Acute rejection favors BO by triggering 
immunologic injuries in epithelial and endothelial cells initiating fibroproliferative 
phase leading to chronic rejection, predominant feature of BOS. (22,24) 
Unfortunately, no uniform diagnostic guidelines to GERD exist: the diagnosis is often 
made clinically based on symptoms like heartburn, yet only 20% of the patients with 
GERD based on 24-hour esophageal pH studies show symptoms (21). It has been 
shown that 38% of transplant patients had no symptoms even though they had 
positive 24-h pH-tests (25). In addition, proton-pump inhibitors may cause unreliable 
symptoms and lead to non-acid reflux (25). Because GERD and microaspiration can 
lead to BOS and subsequent graft loss, it is crucial to be able to identify and measure 
this risk factor. One diagnostic test for esophageal reflux is 24-hour esophageal pH 
study, but it doesn’t reliable indicate tracheal mircoaspiration neither non-acid type of 
reflux with bile acid in addition it is only 50-80% sensitive to reflux (23). pH monitoring 
also has practical problems as all antacid medications has to be suppressed for at least 
5 days beforehand (25), and it is unpleasant for patients and some of them can’t even 
tolerate it at all (23,26).  Other tests to be considered diagnosing GERD are endoscopy, 
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esophageal manometry which may reveal esophageal dysmotility, the measurement of 
esophageal flow, impedance-pH-testing which can detect liquid and gas bolus transit, 
and barium swallow which can also detect dysphagia as endoscopy does. It has also 
been hypothesized that alveolar macrophages could reveal aspiration secondary to 
GERD by phagocytosing aspirated lipids (25). These lipid-laden macrophages from BAL 
samples can possibly be identified by staining the BALF cells with ORO. 
The risk of acute rejection caused by GERD can be reduced by fundoplication before 
transplantation and it may also ease reflux symptoms and improve the quality of life 
(27). In a case report it has been show that a lung transplant patient with bronchial 
inflammation shown by bronchial biopsy had no graft rejection or infection but a 
severe acid reflux. This patient was treated by Nissen fundoplication, which improved 
quickly the patients´ pulmonary function (28). Fundoplication improves mean FEV1 
(28,29) and Hopkins et al in 2010 found that in addition peak pulmonary function and 
even BOS gradus was improved. However, the problem is diverse, many controversies 
exist and therefore fundoplication may not offer that kind of benefit that it was 
believed according to first non-randomized studies (36, Corris, spoken information 
2011) 
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Oil-red-O staining of alveolar macrophages 
 
ORO is and old histological staining method, which is conventionally used in the 
recognition of adipose tissue. ORO staining can also be performed on BAL fluid cells 
(25). BAL is primarily used to reveal infections and to estimate the quality of alveolar 
inflammation. (30) The qualitative analysis of alveolar macrophages has not been used 
in many studies. Some studies have shown that alveolar lipid-laden macrophages 
might reveal aspiration. For example, a correlation between positive ORO-laden 
macrophages and aspiration in various parenchymal lung diseases has been shown 
already in the 1980s (31). Also children with positive 24h-esophageal pH monitoring 
test have been shown to have a higher lipid-laden macrophage index and other BAL 
abnormalities than the pH-negative group (32). The correlation between the lipid index 
and pH monitoring in the post-lung transplant population has also been studied, and 
the results suggested that the lipid index is a potent aspiration marker (25). In that 
particular study was 34 patients and 17 had GERD according to 24h-esophageal pH 
monitoring. For these pH-positive patients the lipid index had an over 80% positive 
predictive value and a 70% negative predictive value (25). On the other hand, Krishnan 
et al studied tracheal aspirates of 64 child patients who had clinically significant 
gastroesophageal reflux symptoms and 34 children who had no reflux symptoms and 
found that only 24 of 64 patients with symptoms showed positive fat-laden 
macrophage index and as many as 14 of 34 children without reflux symptoms were 
positive for lipid-laden macrophages. This study didn’t show any significant correlation 
in mean lipid index between the subgroup of both reflux and symptoms, and the 
subgroup of negative for both these conditions, and therefore the lipid-laden 
macrophages wouldn’t be sensitive neither specific marker for aspiration (33). Others 
have also shown that lipid index didn’t correspond with the severity of patients GERD 
(32). Overall, ORO-positive macrophages as a diagnostic marker of post-lung transplant 
patients’ aspiration is not very widely studied topic and it remains still largely unclear is 
it useful method enough or should there be other options to approach this diagnostic 
problem. 
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Hypothesis and aims 
 
ORO staining of alveolar macrophages has been routinely performed as a diagnostic 
test at the Transplantation laboratory, University of Helsinki from year 2011. In this 
study our goal was to find out, whether there is an association between ORO positivity 
and patients’ clinical state such as BOS, acute graft dysfunction or gastroesophageal 
reflux. We analyzed retrospectively from patient journals the numbers of ORO-positive 
macrophages from routine control bronchoalveolar lavage samples from 54 lung 
transplant patients. We hypothesized that ORO samples are positive in those patients 
who have reflux symptoms, and that there would be less ORO-positivity in patients 
that had had fundoplication. Since reflux is considered to be one of the risk factors for 
BOS, we also hypothesized that patients who have more ORO-positive samples will 
develop BOS sooner than ORO-negative patients. We also studied the relationship of 
acute rejection episodes to ORO-positivity. 
One of our aims was to find out if there is correlation between time and ORO-
positivity. We hypothesized that if ORO-positivity would have time correlation, it 
would decline within time, being the most positive after the transplantation.  
Some patients have undergone fundoplication before transplantation as a preventive 
treatment of reflux, or after the lung transplantation if reflux is noticed afterwards. We 
investigated whether ORO-positivity decreased after fundoplication, hypothesizing 
that ORO samples would be negative after such operation. 
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Methods 
 
 
Subcohort 
 
We screened all lung transplant patient’s medical records (N=127) from the Helsinki 
University Central Hospital and their ORO stainings from BAL samples using electronic 
patient records. We collected information about patients’ clinical events during the 
treatment period in a follow-up setting. The occurrence of BOS, acute graft 
dysfunction or reflux was compared to the proportion of ORO-positive cells in the 
patients’ routine follow-up BAL analysis. Altogether, 127 transplantations have been 
performed in Finland by June 2014. ORO staining has been made for lung transplant 
patients’ BAL samples routinely since 2011. We narrowed down our study population 
to the patients, that had been followed with ORO-staining up from the very first BAL 
sample (N=54). Altogether, we analyzed 414 ORO samples taken from the patients 
included in this study cohort. Every transplant patient was invited for protocol control 
visit regularly: 1, 2, 4, 6, 9 and 12 months after the operation and thereafter annually. 
During every visit each patient undergoes bronchoscopy and BAL samples are taken. 
From the 54 patients’ subcohort we narrowed our study population to patients who 
had relatively often or very high percentage positive ORO samples (N=29). Thus 
subcohort constituted 23% of all lung transplant patients in Finland. 
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Figure 1. Selection of the subcohort presented in this study. The patients that had undergone 
routine follow-up after the time point ORO-staining was taken into diagnostic use (6/2011) 
were screened for positive samples. 
 
 
We calculated the time-dependence of ORO positivity from the entire study cohort, 
but we used only the subcohort to examine the presence of reflux, BOS and rejection 
episodes. Table 1 shows the patient characteristics of the subcohort used in this study.  
 
  
Lung 
trasnplantation 
patients in 
Finland
• All
• N=127
Patients 
transplanted 
after June 2011
• study cohort
• N=54
ORO positive 
samples
• subcohort
• N=22
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Table 1.  
Patient demographics of our subcohort of lung transplant patients that had Oil-red-O positive 
macrophages in their bronchoalveolar lavage samples. Time from transplantation (tx) refers to a 
chosen time point when the data collection was made (7/2014) 
 
  
Patient Sex Time from tx. Reflux Fundoplik. Dg.
1 M 3y2m X X Fibrosis
2 M 3y1m X ARDS
3 F 2y9m X Pulm. hypertension
4 M 2y8m COPD, emphysema
5 F 2y5m X X COPD
6 F 2y4m Idiopathic p.hypertension
7 F 2y3m X Eisenmenger's syndrome
8 F 2y2m X X UIP-fibrosis
9 M 1y11m Fibrosis
10 M 1y10m UIP-fibrosis
11 M 1y10m COPD
12 F 1y8m Emphysema
13 M 1y8m X UIP-fibrosis
14 F 1y8m Cystic fibrosis
15 M 1y8m Fibrosis
16 M 1y7m X Idiopathic fibrosis
17 M 1y2m SLE, pulm. hypertension
18 M 1y COPD
19 M 1y X Fibrosis
20 M 1y PVOD, pulm.hypertension
21 F 11m Emphysema
22 M 9m Idiopathic fibrosis, emphysema
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Figure 2. 
Figure 3. 
Bronchoalveolar lavage 
 
During bronchoscopy, the alveolar space is 
lavaged with 200 ml of physiological saline 
using 20 ml boluses to obtain a 
representative cell population from the 
alveolar space. The BAL cells 
(approximately 100 000 cells) are 
centrifuged to glass objectives using a 
cytocentrifuge. Cytocentrifuge preparates 
are dried overnight and stained with ORO 
reagents. Lipid-containing macrophages 
are seen as bright red coloring (Figures 2 
and 3). Figure 2 shows and overview of 
positive ORO-sample. Engulfed lipids are 
seen as red vacuoles inside the large 
macrophage cell at a high magnification in 
Figure 3. The percentage of positive red 
macrophages is calculated by counting 300 cells. If over a 6% of macrophages are 
positive, the BAL-sample is considered as a positive. 
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Results 
 
 
Our subcohort of 22 patients had altogether 84 positive ORO samples. They had 
together 32 acute rejection episodes and BOS developed into 7 patients, the average 
time for the development of BOS was 15 months.  
Table 1 shows that there are 8 patients in our subcohort of 22 patients, who had reflux 
(36%). The patients with diagnosed reflux based on symptoms, endoscopy or pH-
impedance test, had positive ORO results in 51% of all samples, whereas in the patient 
group with no reflux, 49% of all samples were ORO-positive, suggesting that ORO-
staining positivity is not related to reflux symptoms.  
There were 4 patients who had undergone fundoplication as a treatment, or as a 
preventive method of reflux. Surprisingly, these 4 patients who had undergone 
fundoplication, had more positive ORO samples (average 60.5% of all samples) than 
patients who hadn’t had fundoplication (average 46.9% of all samples). Nevertheless 
since fundoplication can be done before the lung transplantation surgery or after it if 
reflux or aspiration is diagnosed afterwards, these results don’t tell how ORO positivity 
changed after fundoplication. Unfortunately, we did not have many ORO-
measurements from patients´ BAL samples before lung transplantation, due to the fact 
that transplant procedures are centralized to the University of Helsinki, but the 
evaluation for lung transplantation is often performed at local hospitals. One of the 
four fundoplication patients underwent fundoplication before the lung transplantation 
surgery as a preventive treatment so there were no BAL samples taken of him or her 
before fundoplication. Three patients had fundoplication afterwards, so there were 
ORO results before and after the fundoplication and they could be compared. Patient 
number 5 in table 2 was one of these patients, and had 4 ORO results positive before 
the fundoplication, and right after fundoplication ORO staining was 0%. Therefore it 
seems that fundoplication reduced the number of ORO-positive cells in this particular 
patient. Patient number 1 had two positive BAL samples before fundoplication and 
after it, 4 BAL samples were still positive. A third patient had 2 positive BAL samples 
before fundoplication, and after it there were 4 positive samples taken. For these two 
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patients it seems that fundoplication didn’t reduce ORO positivity. One patient who 
had fundoplication before lung transplantation had also positive ORO samples. In 
conclusion, after fundoplication, ORO positivity persisted in many patients.  Figures 4, 
5 and 6 show each fundoplication patients’ variation of ORO results. 
Figure 4 
 
Variation of ORO results in patient number 1 who has undergone fundoplication. 
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Figure 5 
 
Figure 6. 
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ORO positivity didn’t show any correlation with an acute rejection number. In our 
subcohort there was one patient whom all ORO samples were positive, but he or she 
hadn’t suffered from any acute rejection. Patients who had positive samples under 40 
% of all their ORO samples, suffered acute rejection 1.6 times on average, while those 
patients, who had positive samples over 60 % of all their ORO samples, suffered from 
acute rejection only 0.8 times on average.  
BOS correspondence with ORO positivity showed opposite results that we had 
hypothesized. Table 2 shows that 7 patients of our subcohort developed BOS during 
the examination time. If these patients were classified into two categories: those who 
developed BOS in less than 12 months after transplantation, named early BOS group, 
and those who developed BOS more than 12 months after transplantation, named late 
BOS group it could be seen from table 2 that two patients in category first mentioned 
had bigger ORO positivity. Patients in category 1 had 44 % positive samples from all 
their ORO samples while five patients in category 2 had 36 % of their ORO samples 
positive. Thus little fewer ORO positive samples were seen in those patients who 
developed BOS later after surgery than in patients who developed BOS soon. The 
difference in ORO positivity between these late BOS and early BOS groups is 8 
percentages. 15 patients didn’t develop BOS and they had 54 % of their samples ORO 
positive, which is surprisingly the biggest positivity of these three groups. From Table 2 
we can see that patients, who didn’t develop BOS, had ORO positivity extremely 
variable: for example patient 9 had ORO positivity 22 % while patient 22 had ORO 
positivity 100 %. Figure 7 shows that the standard deviation was the smallest in Late 
BOS group.  
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Figure 7. 
The ORO positivity of BOS patients and No BOS patients. 
 
Acute rejection is identified risk factor for BOS. In our subcohort patients who had 
developed BOS, had gone through 1.6 acute rejection episodes on average. Patients 
who hadn’t developed BOS yet, had suffered acute rejection 1.4 times. Therefore there 
were no statistical difference between acute rejection number and BOS developing in 
our subcohort.  
We also examined whether ORO positivity had association with time. ORO samples 
were taken from each patient during the treatment period regularly and it allowed 
seeing if there was any time correlation. Figure 8 shows that ORO positivity didn’t 
increase or decrease as a function of time: r-square- value was 0.0059 %. Acute 
rejection is an identified risk factor for BOS. In our subcohort patients who had 
developed BOS, had gone through 1.6 acute rejection episodes on average. Patients, 
who hadn’t developed BOS yet, had suffered acute rejection 1.4 times. Therefore there 
was no statistical difference between acute rejection number and BOS developing in 
our subcohort.  
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Figure 8.  
An overview of the ORO results of study cohort i.e. a total of 414 samples of 54 patients. For 
each patient, the date of transplantation is standardized to zero and the horizontal axis 
indicates the time difference from the surgery. The vertical axis indicates the ORO positivity. 
The red line is normalized to indicate the overall trend, which is formed by individual data 
points. In this case, the red line shows that ORO results doesn’t comply any relation with time. 
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Table 2. 
Each patient’s ORO results, acute rejection number and the possible BOS developing 
and surgical intervention of reflux are shown. Column ORO/BAL shows how many 
positive ORO samples were in all BAL samples taken. No of Ac Rx – column shows the 
number of acute rejection episodes and BOS developing column tells how soon from 
the transplantation each patient developed BOS. 
Results 
 
 
  
Patient ORO/BAL No of Ac Rx BOS developing Surgical intervention of reflux
1 6/9 0 fundoplication
2 2/6 2 1y2m
3 2/11 0 1y10m
4 3/9 1
5 5/7 0 fundoplication
6 4/8 3 2y2m
7 5/7 1
8 6/9 1 fundoplication
9 2/9 1
10 7/12 2 8m
11 3/9 3
12 6/8 1
13 3/10 1 6m
14 3/8 2 1y6m
15 5/8 2
16 3/8 2 fundoplication
17 3/7 1 1y1m
18 3/6 1
19 3/6 1
20 2/6 3
21 3/7 4
22 5/5 0
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Discussion 
 
Our results do not indicate that ORO staining of BAL fluid can be used to monitor reflux 
in lung transplant patients. ORO staining has been used as an indicator of reflux of lung 
transplant patients in Finland since 2011, but judging from medical records, despite 
the ORO positivity, no treatment will be started based on ORO results unless patient 
also have clinical symptoms. Nowadays ORO staining mostly serves as a supplementary 
and confirming test revealing reflux. Many patients, who were involved in this cohort, 
had ORO results, which appeared to fluctuate randomly and somewhat rapidly, for 
example being totally negative even though patient had reflux symptoms and being 
positive even right after fundoplication. 
We were surprised to find that patients, who had undergone fundoplication, had more 
positive ORO samples than patients who hadn’t undergone fundoplication. In this 
study there happened to be only four patients who had undergone fundoplication, 
which for one’s part decreases also the reliability of the results. It is also possible, that 
in patients that had undergone fundoplication, signs of reflux were still present even 
after the procedure, as we do not know what the exact turnover of lipid-laden 
macrophages in the lung is.   
There are few earlier studies about ORO staining of alveolar macrophages as a 
measurement for reflux. (25,31) As mentioned in this study earlier, reflux and 
microaspiration injures graft and leads to BOS development sooner (18,34). Since all 
lung transplant patients do not have reflux, it is important to recognize those who 
have. In this study there was a 36% subcohort of patients who had been diagnosed to 
have reflux. Therefore it is obvious that patients with terminal lung disease and 
patients who have undergone lung transplantation, have more GERD versus normal 
population. In this study, there was practically no difference in ORO positivity in 
patients with reflux and with no reflux symptoms.  
Reflux is difficult to diagnose since it has no established method and diagnoses are 
usually based only on symptoms. This is why microaspirations often escape noticing 
and therefore there might be silent refluxing patients more in this subcohort than was 
diagnosed, but whose ORO results we don’t pay attention. Anyhow those patients, 
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who had reflux for sure, didn’t have significantly more positive ORO samples. This 
result suggests that the ORO staining cannot be considered as a reliable indicator to 
prove patient’s reflux. 
Lung transplantation offers a beginning of a new life for many lung disease patients 
and at the best it allows a fully normal life. The long-term survival of lung 
transplantation is still overshadowed by many problems like rejections and BOS. 
Therefore it would be very important to understand the etiologic factors of BOS so that 
they could be avoided. Reflux has been one candidate for contributing BOS 
development (25,31). The reliability of ORO staining in revealing reflux has been 
studied before (25,31) and it has given both supporting and negative results. However, 
an extensive similar follow-up as shown here has not been reported previously. 
Because subcohort in this study consists of those patients, who have more ORO 
positive samples of their BAL samples than others, it is presumable that these patients 
would have more reflux and BOS. Concluding the results of this study, it cannot be said 
confidently that ORO results give information about patients’ reflux and thus predict 
BOS development. Therefore our results call for a re-evaluation of ORO staining as a 
routine procedure for lung transplant patients in our center. ORO staining could be 
done, for example, only for those patients with suspected reflux and repetitive acute 
rejection. It is fully possible that also metabolic factors or inhaled drugs can also have 
an impact on ORO results, not only gastric acids. An earlier study showed that HIV-
positive patients had lot of ORO-positivity in BAL (35) suggesting that disturbances in 
fat metabolism may influence this determination.   
Taken together, our study indicates that ORO –staining of BAL is not a reliable method 
in finding reflux in patients that have symptoms. More specific methods, such as 
staining of specific bile acids or their detection from BALF will be needed to be able to 
diagnose silent GERD.  
 
 
References: 
 
21 
 
 
(1) Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, et al. Bronchiolitis 
obliterans syndrome 2001: an update of the diagnostic criteria. The Journal of Heart 
and Lung Transplantation 2002 3;21(3):297-310. 
(2) Gracon ASA, Wilkes DS. Lung transplantation: Chronic allograft dysfunction and 
establishing immune tolerance. Hum Immunol 2014 8;75(8):887-894. 
(3) Bronchiolitis obliterans syndrome complicating lung or heart-lung transplantation. 
Seminars in respiratory and critical care medicine: Copyright© 2003 by Thieme Medical 
Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: 1 (212) 584-4662; 
2003. 
(4) Keller CA, Cagle PT, Brown RW, Noon G, Frost AE. Bronchiolitis obliterans in 
recipients of single, double, and heart-lung transplantation. CHEST Journal 
1995;107(4):973-980. 
(5) Bando K, Paradis IL, Similo S, Konishi H, Komatsu K, Zullo TG, et al. Obliterative 
bronchiolitis after lung and heart-lung transplantation: An analysis of risk factors and 
management. J Thorac Cardiovasc Surg 1995 7;110(1):4-14. 
(6) Kesten S, Maidenberg A, Winton T, Maurer J. Treatment of presumed and proven 
acute rejection following six months of lung transplant survival. Am J Respir Crit Care 
Med 1995 Oct;152(4 Pt 1):1321-1324. 
(7) Girgis RE, Tu I, Berry GJ, Reichenspurner H, Valentine VG, Conte JV, et al. Risk factors 
for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung 
Transplant 1996 Dec;15(12):1200-1208. 
(8) Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: 
a systematic review of recent publications. The Journal of Heart and Lung 
Transplantation 2002 2;21(2):271-281. 
(9) Kroshus TJ, Kshettry VR, Savik K, John R, Hertz MI, Bolman III RM. Risk factors for the 
development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac 
Cardiovasc Surg 1997;114(2):195-202. 
(10) Heng D, Sharples LD, McNeil K, Stewart S, Wreghitt T, Wallwork J. Bronchiolitis 
obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung 
Transplant 1998 Dec;17(12):1255-1263. 
(11) Husain AN, Siddiqui MT, Holmes EW, Chandrasekhar AJ, McCABE M, Radvany R, et 
al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. 
American journal of respiratory and critical care medicine 1999;159(3):829-833. 
(12) Reichenspurner H, Girgis RE, Robbins RC, Conte JV, Nair RV, Valentine V, et al. 
Obliterative bronchiolitis after lung and heart-lung transplantation. Ann Thorac Surg 
1995 12;60(6):1845-1853. 
22 
 
 
(13) Ross DJ, Marchevsky A, Kramer M, Kass RM. "Refractoriness" of airflow obstruction 
associated with isolated lymphocytic bronchiolitis/bronchitis in pulmonary allografts. J 
Heart Lung Transplant 1997 Aug;16(8):832-838. 
(14) Snyder LD, Finlen-Copeland CA, Turbyfill WJ, Howell D, Willner DA, Palmer SM. 
Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung 
transplantation. American journal of respiratory and critical care medicine 
2010;181(12):1391-1396. 
(15) KEENAN RJ, LEGA ME, DUMMER JS, PARADIS IL, DAUBER JH, Rabinowich H, et al. 
Cytomegalovirus serologic status and postoperative infection correlated with risk of 
developing chronic rejection after pulmonary transplantation. Transplantation 
1991;51(2):433-437. 
(16) Boehler A, Estenne M. Post-transplant bronchiolitis obliterans. Eur Respir J 2003 
Dec;22(6):1007-1018. 
(17) De Geest S, Dobbels F, Fluri C, Paris W, Troosters T. Adherence to the therapeutic 
regimen in heart, lung, and heart-lung transplant recipients. J Cardiovasc Nurs 
2005;20(5S):S88-S98. 
(18) D’Ovidio F, Singer LG, Hadjiliadis D, Pierre A, Waddell TK, de Perrot M, et al. 
Prevalence of Gastroesophageal Reflux in End-Stage Lung Disease Candidates for Lung 
Transplant. Ann Thorac Surg 2005 10;80(4):1254-1260. 
(19) Sweet MP, Patti MG, Leard LE, Golden JA, Hays SR, Hoopes C, et al. 
Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung 
transplantation. J Thorac Cardiovasc Surg 2007 4;133(4):1078-1084. 
(20) Patti MG, Tedesco P, Golden J, Hays S, Hoopes C, Meneghetti A, et al. Idiopathic 
pulmonary fibrosis: how often is it really idiopathic? Journal of gastrointestinal surgery 
2005;9(8):1053-1058. 
(21) Young LR, Hadjiliadis D, Davis RD, Palmer SM. Lung transplantation exacerbates 
gastroesophageal reflux disease. CHEST Journal 2003;124(5):1689-1693. 
(22) Nicod LP. Mechanisms of airway obliteration after lung transplantation. 
Proceedings of the American Thoracic Society 2006;3(5):444-449. 
(23) Reder NP, Davis CS, Kovacs EJ, Fisichella PM. The diagnostic value of 
gastroesophageal reflux disease (GERD) symptoms and detection of pepsin and bile 
acids in bronchoalveolar lavage fluid and exhaled breath condensate for identifying lung 
transplantation patients with GERD-induced aspiration. Surg Endosc 2014;28(6):1794-
1800. 
(24) Alho HS, Salminen U, Maasilta PK, Pääkkö P, Harjula ALJ. Epithelial apoptosis in 
experimental obliterative airway disease after lung transplantation. The Journal of Heart 
and Lung Transplantation 2003 9;22(9):1014-1022. 
23 
 
 
(25) Hopkins PM, Kermeen F, Duhig E, Fletcher L, Gradwell J, Whitfield L, et al. Oil red O 
stain of alveolar macrophages is an effective screening test for gastroesophageal reflux 
disease in lung transplant recipients. The Journal of Heart and Lung Transplantation 
2010 8;29(8):859-864. 
(26) Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease 
(GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring 
and an experimental investigation of the role of acid and pepsin in the development of 
laryngeal injury. Laryngoscope 1991 Apr;101(4 Pt 2 Suppl 53):1-78. 
(27) Robertson AG, Krishnan A, Ward C, Pearson JP, Small T, Corris PA, et al. Anti-reflux 
surgery in lung transplant recipients: outcomes and effects on quality of life. Eur Respir J 
2012 Mar;39(3):691-697. 
(28) Palmer SM, Miralles AP, Howell DN, Brazer SR, Tapson VF, Davis RD. 
Gastroesophageal reflux as a reversible cause of allograft dysfunction after lung 
transplantation. CHEST Journal 2000;118(4):1214-1217. 
(29) Hartwig MG, Anderson DJ, Onaitis MW, Reddy S, Snyder LD, Lin SS, et al. 
Fundoplication After Lung Transplantation Prevents the Allograft Dysfunction 
Associated With Reflux. Ann Thorac Surg 2011 8;92(2):462-469. 
(30) Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in 
cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection 
and inflammation. Am J Respir Crit Care Med 1994 Aug;150(2):448-454. 
(31) Corwin RW, Irwin RS. The lipid-laden alveolar macrophage as a marker of aspiration 
in parenchymal lung disease. Am Rev Respir Dis 1985 Sep;132(3):576-581. 
(32) Sacco O, Fregonese B, Silvestri M, Sabatini F, Mattioli G, Rossi G. Bronchoalveolar 
lavage and esophageal pH monitoring data in children with “difficult to treat” 
respiratory symptoms. Pediatr Pulmonol 2000;30(4):313-319. 
(33) Krishnan U, Mitchell JD, Tobias V, Day AS, Bohane TD. Fat laden macrophages in 
tracheal aspirates as a marker of reflux aspiration: a negative report. J Pediatr 
Gastroenterol Nutr 2002;35(3):309-313. 
(34) D’Ovidio F, Mura M, Tsang M, Waddell TK, Hutcheon MA, Singer LG, et al. Bile acid 
aspiration and the development of bronchiolitis obliterans after lung transplantation. J 
Thorac Cardiovasc Surg 2005 5;129(5):1144-1152. 
(35) Lacoste‐Collin L, Martin‐Blondel G, Basset‐Léobon C, Lauwers‐Cancès V, d’Aure D, 
Aziza J, et al. Investigation of the significance of Oil Red O‐positive macrophage excess 
in bronchoalveolar lavage fluid during HIV infection. Cytopathology 2012;23(2):114-119. 
 (36) Hämmäinen, Halme. Keuhkonsiirrot tänään – nykyaikaista hoitoa loppuvaiheen 
keuhkosairauksiin. Suomen lääkärilehti 33/2011 vsk 66, 2333-2338a 
